Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks
Authors' conclusion
SGLT2is improve glycemic control and renal markers in PWS with no weight loss. Close safety monitoring is warranted, particularly regarding renal function in PWS and more generally towards all complex obesity with neurodevelopmental disorders.
Study context
- Population
- Adults with Prader-Willi syndrome and T2D
- Participants
- 48 adults
- Exposure
- SGLT2i vs controls
- SGLT2in = 24
- Outcome
- HbA1c
- Follow-up
- 6 months
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- HbA1c higher at baseline in the SGLT2i group and significantly improved
- P < 0.05
Observational data: associations, not effects.
Further findings
Albumin-to-creatinine ratio · 6 months
- Albumin-to-creatinine ratio decreased significantly
Weight · 6 months
- No significant weight change
Safety
Adverse events · 6 months
%
- Adverse events in treated patients
- 37.5
- Acute kidney injury in treated patients
- 8.3
Original publication
Glycemic and renal effects of SGLT2 Inhibitors in Prader-Willi syndrome: Benefits and risks. Diabetes Metab. Published 18 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →